First patient receives JANX014 dose in Janux’s trial for mCRPC
The trial involves a PSMA-directed T cell engager using Janux’s tumour-activated platform to activate T cells.
News
Precision receives CTA approval to expand ELIMINATE-B study
GlycoNex secures Japan’s PMDA approval for GNX1021 Phase I trial
Vir Biotechnology doses first patient in Phase I VIR-5500 trial
BioNTech and DualityBio report positive data for trastuzumab pamirtecan
AllRock Bio begins patient dosing in Phase IIa ROCSTAR trial
Hemispherian begins Phase I/IIa trial of GLIX1 for GBM
First patient dosed in CatalYm’s Phase IIb visugromab trial
